NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--

新不伦瑞克，新泽西州--（商业资讯）--

Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025..

强生公司（纽约证券交易所代码：JNJ）今天宣布，在Intra-Cellular Therapies公司股东于2025年3月27日批准其待定的收购后，强生公司计划于2025年4月2日左右完成对Intra-Cellular Therapies的收购。

The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by approximately 0.8% with approximately $0.7 billion in incremental sales. Inclusive of the impact of financing costs, Johnson & Johnson expects the transaction to dilute adjusted earnings per share (EPS) by approximately $0.25 in 2025, an improvement from the $0.30 – $0.35 originally estimated on the Company’s Q4 2024 earnings call.

该交易预计将会使强生公司2025年的销售增长加速约0.8%，增加约7亿美元的销售额。包含融资成本的影响在内，强生公司预计这项交易将使其2025年调整后的每股收益（EPS）稀释约0.25美元，较其在2024年第四季度财报电话会议上原先估计的0.30至0.35美元有所改善。

In 2026, Johnson & Johnson expects the earnings dilution to be reduced to approximately $0.21 per share as annualized financing costs are partially offset by operational accretion. Johnson & Johnson will include these estimates in its full-year 2025 financial outlook when it reports first quarter results on April 15, 2025..

2026年，强生公司预计每股收益稀释将减少至约0.21美元，因为年度融资成本部分被运营增益所抵消。强生公司将在2025年4月15日公布第一季度业绩时，将这些估算纳入其2025年全年财务展望中。

Following the completion of the transaction, Intra-Cellular Therapies’ common stock will cease trading on the NASDAQ Global Select Market.

交易完成后，Intra-Cellular Therapies 的普通股将停止在纳斯达克全球精选市场交易。

This release corrects a prior statement that the closing had occurred.

此版本更正了之前关于已完成关闭的声明。

About Johnson & Johnson

关于强生公司

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

在强生，我们相信健康就是一切。我们在医疗保健创新方面的优势使我们能够构建一个世界，在这个世界中，复杂疾病得以预防、治疗和治愈，治疗方法更加智能且侵入性更小，解决方案也更加个性化。凭借我们在创新药物和医疗技术方面的专业知识，我们有能力在当今全面的医疗保健解决方案领域进行创新，以实现明天的突破，并对人类健康产生深远影响。

Learn more at .

了解更多，请访问。

www.jnj.com/

www.jnj.com/

or at

或在

www.innovativemedicine.jnj.com

www.innovativemedicine.jnj.com

. Follow us at

关注我们

@JNJInnovMed

@JNJInnovMed

.

。

CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS:

关于前瞻性声明的注意事项：

This press release contains “forward-looking statements” regarding the acquisition of Intra-Cellular Therapies by Johnson & Johnson and CAPLYTA

本新闻稿包含关于强生公司收购Intra-Cellular Therapies和CAPLYTA的“前瞻性声明”

®

®

and development programs. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson or Intra-Cellular Therapies..

读者应注意不要依赖这些前瞻性陈述。这些陈述基于对未来事件的当前预期。如果基本假设被证明不准确，或已知或未知的风险或不确定性成为现实，实际结果可能与强生公司或Intra-Cellular Therapies的预期和预测大相径庭。

Risks and uncertainties include, but are not limited to: the completion of the acquisition in the expected timeframe; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment..

风险和不确定性包括但不限于：在预期时间内完成收购；产品研究和开发固有的挑战，包括临床成功的不确定性和获得监管批准的不确定性；新产品商业成功的不确定性；生产困难和延误；因产品功效或安全性问题导致的产品召回或监管行动；经济状况，包括汇率和利率波动；全球运营相关的风险；竞争，包括技术进步、竞争对手获得的新产品和专利；专利面临的挑战；适用法律法规的变更，包括税法和全球医疗改革；不利的诉讼或政府行动；医疗保健服务和产品购买者的行为和支出模式的变化或财务困境；以及控制医疗成本的趋势。

In addition, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the programs, products, technologies and employees/operations and clinical work of Intra-Cellular Therapies. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Intra-Cellular Therapies can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024, filed with the SEC on February 13, 2025, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A.

此外，强生公司家族企业能否成功整合Intra-Cellular Therapies的项目、产品、技术以及员工/运营和临床工作也存在风险和不确定性。这些风险、不确定性及其他因素的进一步列表和描述，以及与强生和Intra-Cellular Therapies各自业务相关的总体风险，可参见强生于2025年2月13日提交给美国证券交易委员会的截至2024年12月29日财年的Form 10-K年度报告，特别是标题为“关于前瞻性陈述的警示说明”和“第1A项”的部分。

Risk Factors,” and in Johnson & Johnson’s subsequent filings with the SEC and in Intra-Cellular Therapies’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 21, 2025, including in the sections captioned “Cautionary Statement Regarding Forward-Looking Statements” and “Item 1A.

风险因素”，以及Johnson & Johnson随后向美国证券交易委员会提交的文件和Intra-Cellular Therapies于2025年2月21日向美国证券交易委员会提交的截至2024年12月31日财年的年度报告Form 10-K，其中包括标题为“关于前瞻性陈述的警示声明”和“项目1A”的部分。

Risk Factors,” and in Intra-Cellular Therapies’ subsequent filings with the SEC. Copies of these filings, as well as subsequent filings, are available online at.

“风险因素”，以及Intra-Cellular Therapies公司随后向美国证券交易委员会提交的文件。这些文件的副本，以及随后的文件，均可在线获取。

www.sec.gov

www.sec.gov

,

，

www.jnj.com

www.jnj.com

,

，

www.intracellulartherapies.com

www.intracellulartherapies.com

, or on request from Johnson & Johnson or Intra-Cellular Therapies.

，或者应强生公司或Intra-Cellular Therapies的要求。

Neither Johnson & Johnson nor Intra-Cellular Therapies undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law.

强生公司和Intra-Cellular Therapies均不承担因新信息、未来事件或发展而更新任何前瞻性声明的责任，除非法律要求。

Johnson & Johnson

强生公司

Media Contact:

媒体联系人：

media-relations@its.jnj.com

媒体关系@its.jnj.com

Investor Contact:

投资者联系方式：

investor-relations@its.jnj.com

投资者关系@its.jnj.com

Source: Johnson & Johnson

来源：强生公司